MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SUN PHARMACEUTICAL INDUSTRIES LIMITED (pharmaceuticals)
- SUN PHARMACEUTICAL INDUSTRIES LIMITED Financial Data
Sun Pharma Fact Sheet (SUNP)
Free Report: The Biggest Wealth Creating Opportunity in India. Download Now...
Here is the latest financial fact sheet of Sun Pharma. For more details, see the Sun Pharma quarterly results and Sun Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
SUN PHARMA Price History
| % ch | % | 0.3 |
| No. of shares | m | 2,406.75 |
| % ch week | % | -2.4 |
| % ch 1-mth | % | -10.0 |
| % ch 12-mth | % | -2.4 |
| 52 week H/L | Rs | 484.1/350.4 |
SUN PHARMA Financials
| No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
|---|
| SUN PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 1,074 | 1,201 | 842 | 701 | 679 | |
| Low | Rs | 570 | 706 | 572 | 433 | 375 | |
| Sales per share (Unadj.) | Rs | 132.3 | 118.4 | 131.6 | 110.4 | 121.1 | |
| Earnings per share (Unadj.) | Rs | 21.9 | 23.5 | 32.7 | 10.7 | 13.4 | |
| Diluted earnings per share | Rs | 18.9 | 23.5 | 32.6 | 10.7 | 13.3 | |
| Cash flow per share (Unadj.) | Rs | 27.7 | 27.8 | 37.9 | 17.0 | 20.7 | |
| Dividends per share (Unadj.) | Rs | 3.00 | 1.00 | 3.50 | 2.00 | 2.75 | |
| Adj. dividends per share | Rs | 2.58 | 1.00 | 3.49 | 1.99 | 2.74 | |
| Dividend yield (eoy) | % | 0.4 | 0.1 | 0.5 | 0.4 | 0.5 | |
| Book value per share (Unadj.) | Rs | 135.2 | 137.1 | 152.7 | 159.7 | 172.6 | |
| Adj. book value per share | Rs | 116.4 | 137.0 | 152.2 | 159.2 | 172.1 | |
| Shares outstanding (eoy) | m | 2,071.16 | 2,406.60 | 2,399.26 | 2,399.26 | 2,399.26 | |
| Bonus/Rights/Conversions | - | - | - | - | - | ||
| Price / Sales ratio | x | 6.2 | 8.1 | 5.4 | 5.1 | 4.4 | |
| Avg P/E ratio | x | 37.5 | 40.6 | 21.7 | 53.0 | 39.4 | |
| P/CF ratio (eoy) | x | 29.7 | 34.3 | 18.6 | 33.4 | 25.5 | |
| Price / Book Value ratio | x | 6.1 | 7.0 | 4.6 | 3.5 | 3.1 | |
| Dividend payout | % | 13.7 | 4.3 | 10.7 | 18.7 | 20.6 | |
| Avg Mkt Cap | Rs m | 1,703,011 | 2,294,813 | 1,696,877 | 1,360,021 | 1,264,650 | |
| No. of employees | `000 | NA | 14.7 | 17.5 | 17.8 | 17.5 | |
| Total wages/salary | Rs m | 45,026 | 47,723 | 49,023 | 53,671 | 59,671 | |
| Avg. sales/employee | Rs Th | NM | 19,317.2 | 18,028.3 | 14,890.9 | 16,608.1 | |
| Avg. wages/employee | Rs Th | NM | 3,236.1 | 2,798.8 | 3,017.1 | 3,409.6 | |
| Avg. net profit/employee | Rs Th | NM | 3,836.9 | 4,473.8 | 1,443.6 | 1,833.8 | |
| SUN PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 273,920 | 284,870 | 315,784 | 264,895 | 290,659 | |
| Other income | Rs m | 5,477 | 6,583 | 6,232 | 8,388 | 10,255 | |
| Total revenues | Rs m | 279,397 | 291,453 | 322,016 | 273,282 | 300,914 | |
| Gross profit | Rs m | 78,667 | 81,583 | 100,893 | 56,081 | 63,076 | |
| Depreciation | Rs m | 11,947 | 10,375 | 12,648 | 14,998 | 17,533 | |
| Interest | Rs m | 5,790 | 5,232 | 3,998 | 5,176 | 5,553 | |
| Profit before tax | Rs m | 66,407 | 72,558 | 90,479 | 44,295 | 50,246 | |
| Minority Interest | Rs m | -9,363 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | -126 | 15 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | -2,378 | -6,852 | 0 | -9,505 | -12,144 | |
| Tax | Rs m | 9,147 | 9,138 | 12,116 | 9,110 | 6,009 | |
| Profit after tax | Rs m | 45,394 | 56,583 | 78,363 | 25,679 | 32,093 | |
| Gross profit margin | % | 28.7 | 28.6 | 31.9 | 21.2 | 21.7 | |
| Effective tax rate | % | 13.8 | 12.6 | 13.4 | 20.6 | 12.0 | |
| Net profit margin | % | 16.6 | 19.9 | 24.8 | 9.7 | 11.0 | |
| SUN PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 288,782 | 299,413 | 329,537 | 316,359 | 310,692 | |
| Current liabilities | Rs m | 153,294 | 131,440 | 178,870 | 198,643 | 173,396 | |
| Net working cap to sales | % | 49.5 | 59.0 | 47.7 | 44.4 | 47.2 | |
| Current ratio | x | 1.9 | 2.3 | 1.8 | 1.6 | 1.8 | |
| Inventory Days | Days | 76 | 82 | 79 | 95 | 99 | |
| Debtors Days | Days | 68 | 87 | 83 | 108 | 112 | |
| Net fixed assets | Rs m | 151,694 | 180,477 | 204,766 | 213,178 | 232,477 | |
| Share capital | Rs m | 2,071 | 2,407 | 2,399 | 2,399 | 2,399 | |
| "Free" reserves | Rs m | 278,009 | 327,418 | 363,997 | 380,742 | 411,691 | |
| Net worth | Rs m | 280,080 | 329,825 | 366,397 | 383,141 | 414,091 | |
| Long term debt | Rs m | 13,598 | 31,103 | 14,361 | 17,721 | 15,226 | |
| Total assets | Rs m | 501,601 | 555,303 | 614,102 | 645,164 | 646,938 | |
| Interest coverage | x | 12.5 | 14.9 | 23.6 | 9.6 | 10.0 | |
| Debt to equity ratio | x | 0 | 0.1 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | |
| Return on assets | % | 10.2 | 11.1 | 13.4 | 4.8 | 5.8 | |
| Return on equity | % | 16.2 | 17.2 | 21.4 | 6.7 | 7.8 | |
| Return on capital | % | 20.5 | 19.7 | 24.8 | 10.0 | 10.2 | |
| Exports to sales | % | 16.9 | 13.9 | 0 | 0 | 0 | |
| Imports to sales | % | 4.5 | 3.1 | 0 | 0 | 0 | |
| Exports (fob) | Rs m | 46,235 | 39,572 | 0 | 0 | 0 | |
| Imports (cif) | Rs m | 12,229 | 8,882 | 0 | 0 | 0 | |
| Fx inflow | Rs m | 48,706 | 42,171 | 44,118 | 51,403 | 66,025 | |
| Fx outflow | Rs m | 25,564 | 21,583 | 24,484 | 32,233 | 38,610 | |
| Net fx | Rs m | 23,142 | 20,588 | 19,634 | 19,170 | 27,415 | |
| SUN PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 56,157 | 66,859 | 70,822 | 39,072 | 21,965 | |
| From Investments | Rs m | -28,657 | -43,716 | -42,216 | -33,708 | -6,813 | |
| From Financial Activity | Rs m | -11,865 | -18,885 | -22,854 | -15,393 | -27,305 | |
| Net Cashflow | Rs m | 15,635 | 8,482 | 6,107 | -7,359 | -8,442 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Israel Makov | COMP SEC: Sunil R. Ajmera | YEAR OF INC: 1993 | BSE CODE: 524715 | FV (Rs): 1 | DIV YIELD (%): 0.7 |
Read: SUN PHARMA 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: GLENMARK PHARMA ELDER PHARMA AMAR REMEDIES J.B.CHEMICALS FDC LTD.
Compare SUN PHARMA With: GLENMARK PHARMA ELDER PHARMA AMAR REMEDIES J.B.CHEMICALS FDC LTD.
Compare SUN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)
Indian stock markets mostly remained in the negative zone during the week except for Wednesday.
Views on news
SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)
Feb 7, 2020 | Updated on Feb 7, 2020For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsMost Popular
This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years) (Profit Hunter)
Feb 11, 2020A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.
Here's Why I Recommended 15 Stocks in One Day Flat 
(Views On News)
Feb 14, 2020
This proven strategy can give big returns in quick time.
CoronaVirus' Impact on Indian Markets - And One Stock With the Potential to Make Crores... (Profit Hunter)
Feb 7, 2020Even as the experts come to grips with impact of Coronavirus contagion on Indian stocks and economy, here's a stock not just immune to macro threats, but with the potential to offer crores in the long term.
Will Algo Traders Take Away All Your Profits? (Fast Profits Daily)
Feb 11, 2020How to fight back against algo trading systems.
A Megatrend to Help You Find the Best Stocks of the Next Decade (The 5 Minute Wrapup)
Feb 12, 2020Recent events have put climate change into the spotlight. Here's how you should play this megatrend...
More|
| |
OUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- 7 Stocks to Ride the Coming Rebirth of India Rally. Full Details Here...
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.